Published online Mar 27, 2024. doi: 10.4254/wjh.v16.i3.439
Peer-review started: November 8, 2023
First decision: November 30, 2023
Revised: December 22, 2023
Accepted: February 18, 2024
Article in press: February 18, 2024
Published online: March 27, 2024
Processing time: 140 Days and 4.8 Hours
Hepatocellular carcinoma (HCC) has a poor prognosis and heavy disease burden, but its treatment methods are not satisfactory.
High sterol O-acyltransferase 1 (SOAT1) expression has been shown to be associated with several tumor types (liver cancer, pancreatic cancer, and prostate cancer) and with diagnosis and treatment. However, the relationship between SOAT1 expression and HCC remains unclear. As patients would greatly benefit from early detection of HCC, the complementary study of HCC-associated proteins in serum samples using state-of-the-art proteomics would also be a very attractive direction for future research. Therefore, SOAT1 may serve as a novel target that drives the development of immunotherapy and metabolic therapy.
This study aimed to investigate the correlation between SOAT1 expression and HCC, using RNA-seq and gene expression data of The Cancer Genome Atlas (TCGA)-liver hepatocellular carcinoma (LIHC) and pan-cancer. Our findings demonstrate that SOAT1 may serve as a new target for HCC treatment and promote the development of new strategies for immunotherapy and metabolic therapy.
The correlation between SOAT1 expression and HCC was analyzed. Cox hazard regression models were used to investigate the prognostic value of SOAT1. Overall survival and disease-specific survival were also explored in TCGA-LIHC. Moreover, the biological processes and functional pathways regulated by SOAT1 were characterized using gene ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of differentially expressed genes. To better understand the regulatory mechanism of SOAT1 in HCC, protein–protein interaction network and co-expression analyses of SOAT1 in HCC were conducted.
SOAT1 and SOAT2 were highly expressed in unpaired samples, while only SOAT1 was highly expressed in paired samples. The area under the receiver operating characteristic curve of SOAT1 expression in tumor samples from LIHC patients compared with para-carcinoma tissues was 0.748, while the area under the curve of SOAT1 expression in tumor samples from LIHC patients compared with GTEx was 0.676. Patients with higher SOAT1 expression had lower survival rates. Results from GO/KEGG and gene set enrichment analyses suggested that the PI3K/AKT signaling pathway, the IL-18 signaling pathway, the calcium signaling pathway, secreted factors, the Wnt signaling pathway, the Jak/STAT signaling pathway, the MAPK family signaling pathway, and cell–cell communication were involved in such association. SOAT1 expression was positively associated with the abundance of macrophages, Th2 cells, T helper cells, CD56bright natural killer cells, and Th1 cells, and negatively linked to the abundance of Th17 cells, dendritic cells, and cytotoxic cells.
As patients would greatly benefit from early detection of hepatocellular carcinoma, the complementary study of hepatocellular carcinoma-associated proteins in serum samples using state-of-the-art proteomics would be a very attractive direction for future exploration.
The identification of other HCC proteins involved in this multigenic heterogeneous cancer type is an important objective for future research.